$Roivant Sciences (ROIV.US)$ Which companies have drugs in c...

$Roivant Sciences (ROIV.US)$ Which companies have drugs in clinical trials phase 2-3 for treatment of ulcerative colitis (UC) and Crohn's disease (CD) targeting tumor necrosis factor-like ligand 1A (TL1A)? There are only two. One is Prometheus Biosciences, which was acquired by Merck for ~$11 Billion (https://www.merck.com/news/merck-completes-acquisition-of-prometheus-biosciences-inc/) for this specific type of drug in phase 2a for UC just months ago. The other one is Roivant, whose RVT-3101 has entered phase 3 for UC (https://www.roivant.com/pipeline). That's why savvy investors believe a similar buyout/license deal will happen soon. Besides RVT-3101, Roivant also has many other promising drugs with blockbuster potentials in development with positive results, not to mention its VTAMA which was already marketed with blockbuster potential as well. As of now, Roivant's market cap is only ~$8Billion.